Rheumatology and Diabetes news: Lower risk for gout observed with SGLT2 inhibitors vs GLP1 agonists in type 2 diabetes

https://www.rheumatologyadvisor.com/home/conference-highlights/acr-2019/lower-risk-for-gout-with-sglt2-inhibitors-vs-glp1-agonists-in-type-2-diabetes/